Your Article Summary
A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression
Journal of Acquired Immune Deficiency Syndromes, 06/25/09
Martinez E et al. - In HIV-1-infected patients with virological suppression, abacavir/lamivudine did not meet the noninferiority outcome for treatment efficacy compared with tenofovir/emtricitabine.
Related Articles
Prevalence and Correlates of Elevated Body Mass Index among HIV-Positive and HIV-Negative Women in the Womens Interagency HIV Study
AIDS Patient Care and STDs, 11/19/09
Relevance Score: 95%
Effectiveness of Increasing Emergency Department Patients' Self-perceived Risk for Being Human Immunodeficiency Virus (HIV) Infected Through Audio Computer Self-interview–based Feedback About Reported HIV Risk Behaviors
Academic Emergency Medicine, 11/11/09
Relevance Score: 95%
HIV-Specific Health Care Utilization and Mortality among Tuberculosis/HIV Coinfected Persons
AIDS Patient Care and STDs, 10/06/09
Relevance Score: 95%
Mediators of HIV-related stigma and risk behavior in HIV infected young women
AIDS Care, 11/12/09
Relevance Score: 94%
Sperm May Play Leading Role In Spreading HIV
ScienceDaily, 10/27/09
Relevance Score: 94%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09
Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09

See Latest Articles